drugset

drugset / Trial / NCT06718686

Rifaximin SSD in Dementia Trial

NCT06718686 ↗

Phase 1/2 Recruiting 20 enrolled Jasmohan Bajaj Bausch Health Americas, Inc. · collab

NaSequentialTriple-blindTreatment

Summary

Using a new formulation of rifaximin, a non-absorbable antibiotic, to test if it can affect microbes in the gut of patients with dementia favorably.

Timeline

Start: 2024-12-30
Primary completion: 2027-10-30
Completion: 2027-12-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rifaximin	Other / unclassified	40 mg	—

Indications